Objective: The present study was designed to evaluate the possible association of
three different HSP70; HSPA1A, HSPA1B and HSPA1L; gene polymorphisms with
pre-eclampsia and the possible correlation with serum levels of HSP70. Method: The
study included 46 women with pre-eclampsia as group I (GI) and twenty two
normotensive pregnant controls representing group II (GII). All candidates of the
study were subjected to the following: Measurement of human HSP70 concentrations
in serum, molecular analysis for PCR amplification of the HSPA1A G (190)C regions,
HSPA1B A(1267)G regions, HSPA1L T(2437)C regions. Results: Serum HSP70 was
found to be significantly increased in pre-eclamptic patients when compared to
normal pregnancy. HSPA1A (190) GC and HSPA1B (1267) GG genotypes occurred
more frequently in pre-eclamptic patients compared to healthy controls (p < 0.03).
Significant difference was found in the distribution of HSPA1B (1267) AG genotype
between the pre-eclamptic and control group (p < 0.004). Distribution of HSPA1L
T(2437)C gene was found similar in the Pre-eclamptic and control group. Cases with
HSPA1A G(190)C had a mean serum level of HSP70 that is 1.4 ng/ml more than
those without HSPA1A G(190)C polymorphism. A significant negative association
was noted between maternal age and serum Hsp70 concentration in both preeclampsia
and healthy pregnant women. Conclusion: Elevated serum HSP70 level in
pre-eclamptic patients seems to reflect the burden of oxidative stress taking place im
pre-eclampsia. HSP70 polymorphism may affect the serum level as proved by
increase in the mean serum level of HSP70 by 1.4 ng/ml in those with HSPA1A
G(190)C polymorphism .